Webinar: Navigate the Maze of Import & Export Pharma Regulations

Apply correct tariff classification, utilize niche programs to relieve duty burdens for pharma ingredients

A typical Phase III clinical study may be conducted over multiple global regions and many countries, each location with their own regulatory bodies and in the case of many target emerging economies, a constantly moving set of goal posts. The growth of Biological pharmaceuticals, further adding to the complexity and the need for an efficient and compliant supply chain.

Over 80% of API and chemical precursors are produced outside of the US, typically in India, China and Europe, and many of the leading pharmaceutical and contract manufacturing companies headquartered here, optimizing a complex pharmaceutical supply chain that covers the globe is no longer a simple logistics & transportation exercise.

A thorough working knowledge of import and export regulations can make the difference between efficient production, a successful product launch and drug shortages significant delays to market.

This webinar will attempt to shine a light on the import and export process and help the participants avoiding common pitfalls that lead to:

• Costly delays
• Over payment of duties, taxes & fees.
• Missed Manufacturing slots
• Inventory deterioration
• Additional QC
• Import license exhaustion on quantity or date expiry
• Impact to patient recruitment & continued treatment.